Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.
Dr. Taofeek Owonikoko reviews why we often see brain metastases develop as a first or only site of progression in patients with NSCLC and a driver mutation.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Drs. Ben Solomon, Leora Horn, & Jack West evaluate the evidence and consider whether there are clinically significant differences among the second generation ALK inhibitors that would lead to a reason to prefer one over another for a particular patient.
Drs. Leora Horn, Ben Solomon, & Jack West discuss the open question of whether there are clinically significant differences among leading EGFR tyrosine kinases based on the specific EGFR mutation to be treated.
Wondering if anyone has info on compatibility of berberine with Tarceva. I called Genentech but they didn’t know. I am taking it because it has...
I can't seem to find an answer to my question concerning is it is better to start treatment sooner for a cancerous tumor when it is small and less...
(djorner3) I can’t seem to find an answer to my question concerning is it is better to start treatment sooner for a cancerous tumor when it is small...
Wondering if anyone has info on compatibility of berberine with Tarceva. I called Genentech but they didn’t know. I am taking it because it has...
cards7up posted a thread over on inspire today "5 Years Ago Today" that tells her remarkable story of 5 year survival after a relapse of NSCLC. I...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.